Full-Time

Senior Engineer

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$115.5k - $156.3k/yr

+ Annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

In Person

Up to 10% travel to domestic and international sites is required.

Category
Process Engineering
Required Skills
LLM
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master's degree with 2 years of engineering and/or operations experience, or a bachelor's degree with 4 years of engineering and/or operations experience, or an associate's degree with 8 years of engineering and/or operations experience, or a high school diploma/GED with 10 years of engineering and/or operations experience is required.
  • Experience with visual inspection, biologics drug product development, commercialization, or lifecycle management is required for the role's technical scope.
  • Experience developing inspection strategies, characterization protocols, offline testing methods, and product quality impact assessments is required.
  • Proficiency in data analysis using advanced statistical and analytical techniques and statistical analysis software is required.
  • Knowledge of applicable FDA, European Union, and international quality standards is required.
  • Ability to work independently, manage work packages, communicate status, and escalate issues appropriately is required.
Responsibilities
  • Serve as the technical subject matter expert for visual inspection and provide leadership in troubleshooting complex inspection-related issues.
  • Participate in Drug Product Commercialization Teams conducting process development on pipeline products and supporting commercial products in lifecycle management.
  • Own and continuously improve the business process for defect kit preparation and management supporting visual inspection development studies.
  • Establish testing strategies and develop characterization protocols, offline testing methods, and product quality impact assessments for product teams.
  • Interface with inspection teams across manufacturing sites and communicate site capabilities, best practices, and lessons learned.
  • Leverage advanced artificial intelligence technologies, including generative artificial intelligence, large language models, and in silico modeling, to drive innovation and accelerate research, development, and testing processes.
  • Plan, design, execute, and document laboratory studies related to formulation, aseptic processing, visual inspection, and fill/finish process development in support of product commercialization and lifecycle management.
  • Apply basic science and engineering skills and first-principles modeling to solve technical problems.
  • Perform data analysis using advanced statistical and analytical techniques.
  • Provide support to clinical and commercial fill/finish manufacturing operations through process capability analysis, troubleshooting, root cause analysis, and product impact assessments for non-conformance investigations and process changes or improvements.
  • Author and review guideline documents, technical protocols, reports, product impact assessments, and regulatory sections supporting investigational new drug and marketing application submissions.
  • Deliver progress reports and presentations to ensure management awareness and engagement regarding current status, advancement, and future program functional needs.
  • Conduct risk assessments for inspection operations and propose or implement appropriate corrective and preventive actions.
  • Identify and implement operational opportunities for current and new inspection operations.
  • Lead cross-site teams supporting these activities and provide recommendations to management.
  • Develop validation plans, installation/operational/qualification protocols, and performance qualifications.
  • Ensure inspection operations meet applicable quality requirements, laws, and FDA, European Union, and international standards.
  • Assist in deviation and exception resolution and root cause analysis.
  • Coordinate and organize resources needed to complete tasks.
Desired Qualifications
  • A PhD with 2 years of industry experience is preferred.
  • Industry experience with development and manufacturing visual inspection is preferred.
  • Experience with Knapp studies is preferred.
  • Experience with packaging and inspection equipment is preferred.
  • Previous pharmaceutical inspection experience is preferred.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.